NasdaqCM - Delayed Quote USD

Lixte Biotechnology Holdings, Inc. (LIXT)

1.4100
+0.2400
+(20.51%)
At close: June 2 at 4:00:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
0
0
0
Operating Expense
3,312.8500
3,572.7890
5,090.2360
6,311.4810
6,720.4450
Operating Income
-3,312.8500
-3,572.7890
-5,090.2360
-6,311.4810
-6,720.4450
Net Non Operating Interest Income Expense
-8.1400
-9.7730
1.2530
2.3200
-6.7880
Other Income Expense
-3.2080
-3.4030
1.9540
-3.3740
-1.1630
Pretax Income
-3,324.1980
-3,585.9650
-5,087.0290
-6,312.5350
-6,728.3960
Net Income Common Stockholders
-3,324.1980
-3,585.9650
-5,087.0290
-6,312.5350
-6,728.3960
Diluted NI Available to Com Stockholders
-3,324.1980
-3,585.9650
-5,087.0290
-6,312.5350
-6,728.3960
Basic EPS
-1.45
-1.59
-2.66
-3.99
-5.00
Diluted EPS
-1.45
-1.59
-2.66
-3.99
-5.00
Basic Average Shares
2,304.8460
2,249.2900
1,915.8380
1,582.0290
1,347.3830
Diluted Average Shares
2,304.8460
2,249.2900
1,915.8380
1,582.0290
1,347.3830
Total Operating Income as Reported
-3,312.8500
-3,572.7890
-5,090.2360
-6,311.4810
-6,720.4450
Total Expenses
3,312.8500
3,572.7890
5,090.2360
6,311.4810
6,720.4450
Net Income from Continuing & Discontinued Operation
-3,324.1980
-3,585.9650
-5,087.0290
-6,312.5350
-6,728.3960
Normalized Income
-3,320.9900
-3,582.5620
-5,088.9830
-6,309.1610
-6,727.2330
Interest Income
4.6300
7.0480
17.4860
11.1950
0.6260
Interest Expense
12.7700
16.8210
16.2330
8.8750
7.4140
Net Interest Income
-8.1400
-9.7730
1.2530
2.3200
-6.7880
EBIT
-3,311.4280
-3,569.1440
-5,070.7960
-6,303.6600
-6,720.9820
EBITDA
-3,311.4280
-3,569.1440
-5,070.7960
-6,303.6600
-6,720.9820
Net Income from Continuing Operation Net Minority Interest
-3,324.1980
-3,585.9650
-5,087.0290
-6,312.5350
-6,728.3960
Total Unusual Items Excluding Goodwill
-3.2080
-3.4030
1.9540
-3.3740
-1.1630
Total Unusual Items
-3.2080
-3.4030
1.9540
-3.3740
-1.1630
Normalized EBITDA
-3,308.2200
-3,565.7410
-5,072.7500
-6,300.2860
-6,719.8190
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 10/25/2007

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

DRMA Dermata Therapeutics, Inc.
0.7000
-2.79%
 
EDSA Edesa Biotech, Inc.
1.9900
+1.02%
 
TSBX Turnstone Biologics Corp.
0.3127
-2.31%
 
LEXX Lexaria Bioscience Corp.
0.9771
-3.26%
 
ARTV Artiva Biotherapeutics, Inc.
1.9400
+0.52%
 
ENSC Ensysce Biosciences, Inc.
2.2200
0.00%
 
XBIO Xenetic Biosciences, Inc.
3.2900
+9.67%
 
SPRC SciSparc Ltd.
0.3160
+0.70%
 
PALI Palisade Bio, Inc.
0.7600
+2.43%
 
NXTC NextCure, Inc.
0.4803
-2.46%